Gliclazide MR in the management of Type 2 Diabetes Mellitus

download Gliclazide MR in the management of Type 2 Diabetes Mellitus

of 53

Embed Size (px)

description

Symposium on 10th June, 2013. Presented by Dr. Nazma Akhter (Phase B Resident, Endocrinology)

Transcript of Gliclazide MR in the management of Type 2 Diabetes Mellitus

  • 1.GLICLAZIDE MR IN THEMANAGEMENT OF TYPE 2 DMDr. Nazma AkhtarResident phase BDepartment of EndocrinologyBSMMU

2. 3/28/2013 3 3. 3/28/2013 4 4. SULFONYLUREA: OAD agentMode of action: Sulfonylureas act directly on the - cells of the islets ofLangerhans to stimulate insulin secretion They enter the cell and bind to the cytosolic surface of thesulfonylurea receptor 1 Binding of a sulfonylurea closes the K + ATP channel, reducingthe efflux of potassium enabling membrane depolarization Localized membrane depolarization opens adjacent voltage -dependent L - type calcium channels Increasing calcium influx and raising the cytosolic freecalcium concentration Mediate the exocytotic release of insulin granules 5. Classification Divided into first and second generationagents In general, the second-generation agents Are more potent Have fewer adverse effects and drug-druginteractions 6. Extended release preparations Extended-release glipizide and glimepiride arepreferred agents because- they can be given once daily- involve a relatively low risk ofhypoglycemia-low weight gain 7. Modified release preparations A modified release (MR) formulation ofgliclazide has been introduced for once - dailydosing Interestingly, the 30 mg preparation ofgliclazide MR gives similar efficacy to 80 mg ofunmodified gliclazide and reduces risk ofsevere hypoglycemia 8. Target HbA1c